Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isotechnika has reported that the process for gaining a European patent for its mTOR inhibitor TAFA93 has commenced following the issuance of the corresponding Swedish patent.
Subscribe to our email newsletter
In accordance with the European Patent Convention, this patent will be granted in a total of 31 European countries of which patents for the remaining 30 countries will be forthcoming.
TAFA93, an advanced pro-drug of rapamycin is a novel small molecule mTOR inhibitor, which is a class of drugs currently used in the prevention of organ rejection in transplantation.
Robert Foster, chairman & CEO of Isotechnika, said: “This allows us to broaden our product pipeline while maintaining our primary focus in transplantation.”